QTTB Stock Q32 Bio Inc.
WATCH US · NasdaqCMSpeculative upside remains compelling if clinical results validate the platform.
Signal breakdown
- ▸Potential catalyst exists, but confirmation is still limited.
- ▾Below 50-day MA (-23.15%)
Is QTTB a buy right now?
Trend: QTTB is trading below the 50-day average (-23.11%), RSI 58 — neutral momentum, with a 3-month return of -46.21%.
Valuation & quality: Q32 Bio Inc. trades on a trailing P/E of 2.7, forward P/E -8.3, price-to-book 1.89; fundamentals show net margin 62.9%, return on equity 72.1%.
Analyst consensus: 6 analysts have a mean 12-month price target of $39.67 (+369.4% vs the last close; range $29.00 – $59.00), consensus rating “strong buy”.
Our screen: WATCH (score 0) — Speculative upside remains compelling if clinical results validate the platform.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +40.80% | -12.80% | +97.30% | +15.30% | +23.10% | -5.20% | -44.40% | +2.20% |
Fundamentals
Analyst price target
Technical signals
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Sector: Healthcare · Industry: Biotechnology · United States · 22 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.